The efficacy of bromfenac ophthalmic solution 0.07% dosed once daily in achieving zero-to-trace anterior chamber cell severity following cataract surgery

References

• HarrerAGerstmeyerKHirnschallNPesudovsKLundströmMFindlOImpact of bilateral cataract surgery on vision-related activity limitationsJ Cataract Refract Surg201339568068523535380
   PubMed Web of Science ®Google Scholar
• Porela-TiihonenSKaarnirantaKKokkiHPostoperative pain after cataract surgeryJ Cataract Refract Surg201339578979823608571
   PubMed Web of Science ®Google Scholar
• MonnetDTépenierLBrézinAPObjective assessment of inflammation after cataract surgery: comparison of 3 similar intraocular lens modelsJ Cataract Refract Surg200935467768119304088
   PubMed Web of Science ®Google Scholar
• Porela-TiihonenSKaarnirantaKKokkiMPurhonenSKokkiHA prospective study on postoperative pain after cataract surgeryClin Ophthalmol201371429143523885165
   PubMedGoogle Scholar
• GulkilikGKocaboraSTaskapiliMEnginGCystoid macular edema after phacoemulsification: risk factors and effect on visual acuityCan J Ophthalmol200641669970317224950
   PubMed Web of Science ®Google Scholar
• O’BrienTPEmerging guidelines for use of NSAID therapy to optimize cataract surgery patient careCurr Med Res Opin20052171131113716004683
   PubMed Web of Science ®Google Scholar
• AhujaMDhakeASSharmaSKMajumdarDKTopical ocular delivery of NSAIDsAAPS J200810222924118437583
   PubMed Web of Science ®Google Scholar
• ChoHWolfKJWolfEJManagement of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solutionClin Ophthalmol2009319921019668566
   PubMedGoogle Scholar
• DonnenfeldEDHollandEJStewartRHGowJAGrilloneLRBromfenac Ophthalmic Solution 0.09% (Xibrom) Study Group. Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammationOphthalmology200711491653166217445902
   PubMed Web of Science ®Google Scholar
• HendersonBAGaytonJLChandlerSPGowJAKlierSMMcNamaraTRBromfenac Ophthalmic Solution (Bromday) Once Daily Study Group. Safety and efficacy of bromfenac ophthalmic solution (Bromday) dosed once daily for postoperative ocular inflammation and painOphthalmology2011118112120212721762992
   PubMed Web of Science ®Google Scholar
• RidgwayDAnalgesics for acute pain: Meeting the United States Food and Drug Administration’s requirements for proof of efficacyClin J Pain200420312313215100587
   PubMed Web of Science ®Google Scholar
• SilversteinSMCableMGSadriEBromfenac Ophthalmic Solution Once Daily (Bromday) Study Group. Once daily dosing of bromfenac ophthalmic solution 0.09% for postoperative ocular inflammation and painCurr Med Res Opin20112791693170321751945
   PubMed Web of Science ®Google Scholar
• MiyakeKOgawaTTajikaTGowJAMcNamaraTROcular pharmacokinetics of a single dose of bromfenac sodium ophthalmic solution 0.1% in human aqueous humorJ Ocul Pharmacol Ther200824657357819049295
   PubMed Web of Science ®Google Scholar
• MukaiKMatsushimaHGotohNEfficacy of ophthalmic nonsteroidal antiinflammatory drugs in suppressing anterior capsule contraction and secondary posterior capsule opacificationJ Cataract Refract Surg20093591614161819683162
   PubMed Web of Science ®Google Scholar
• ColinJThe role of NSAIDs in the management of postoperative ophthalmic inflammationDrugs20076791291130817547472
   PubMed Web of Science ®Google Scholar
• CsukasSPatersonCABrownKBhattacherjeePTime course of rabbit ocular inflammatory response and mediator release after intravitreal endotoxinInvest Ophthalmol Vis Sci19903123823872154416
   PubMed Web of Science ®Google Scholar
• KoayPThe emerging roles of topical non-steroidal anti-inflammatory agents in ophthalmologyBr J Ophthalmol19968054804858695573
   PubMed Web of Science ®Google Scholar
• WarnerTDMitchellJACyclooxygenases: new forms, new inhibitors, and lessons from the clinicFASEB J200418779080415117884
   PubMed Web of Science ®Google Scholar
• WaltersTRaizmanMErnestPGaytonJLehmannRIn vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenacJ Cataract Refract Surg20073391539154517720067
   PubMed Web of Science ®Google Scholar
• Bromday^® (bromfenac ophthalmic solution) 0.09% [package insert]Irvine, CAISTA Pharmaceuticals, Inc2011
   Google Scholar
• SancilioLFNolanJCWagnerLEWardJWThe analgesic and anti-inflammatory activity and pharmacologic properties of bromfenacArzneimittelforschung19873755135193497637
   PubMed Web of Science ®Google Scholar
• WalshDAMoranHWShambleeDAAntiinflammatory agents. 3. Synthesis and pharmacological evaluation of 2-amino-3-benzoylphenylacetic acid and analoguesJ Med Chem19842711137913886436487
   PubMed Web of Science ®Google Scholar
• RuizJLópezMMilàJLozoyaELozanoJJPouplanaRQSAR and conformational analysis of the antiinflammatory agent amfenac and analoguesJ Comput Aided Mol Des1993721831988320556
   PubMed Web of Science ®Google Scholar
• Bronuck^® (bromfenac ophthalmic solution) 01% [package insert] OsakaJapanSenju Pharmaceutical Co2009
   Google Scholar
• Xibrom™ (bromfenac ophthalmic solution) 0.09% [package insert]Irvine, CAISTA Pharmaceuticals2010
   Google Scholar
• Bausch & Lomb IncorporatedEfficacy of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery Available from: http://clinicaltrials.gov/show/NCT01367249 NLM identifier: NCT01367249Accessed March 3, 2014
   Google Scholar
• WaltersTRGoldbergDFPeaceJHGowJABromfenac Ophthalmic Solution 0.07% Once Daily Study Group. Bromfenac ophthalmic solution 0.07% dosed once daily for cataract surgery: results of 2 randomized controlled trialsOphthalmology20141211253324021896
   PubMed Web of Science ®Google Scholar
• Miyake-KashimaMTakanoYTanakaMComparison of 0.1% bromfenac sodium and 0.1% pemirolast potassium for the treatment of allergic conjunctivitisJpn J Ophthalmol200448658759015592786
   PubMed Web of Science ®Google Scholar
• PriceFWNew pieces for the puzzle: nonsteroidal anti-inflammatory drugs and corneal ulcersJ Cataract Refract Surg20002691263126511020603
   PubMed Web of Science ®Google Scholar
• CarreñoEPorteroAGalarretaDJHerrerasJMUpdate on twice-daily bromfenac sodium sesquihydrate to treat postoperative ocular inflammation following cataract extractionClin Ophthalmol2012663764422570544
   PubMedGoogle Scholar
• DonnenfeldEDDonnenfeldAGlobal experience with Xibrom (bromfenac ophthalmic solution) 0.09%: the first twice-daily ophthalmic nonsteroidal anti-inflammatory drugInt Ophthalmol Clin2006464214017060789
   PubMedGoogle Scholar
• Prolensa™ (bromfenac ophthalmic solution) 0.07% [package insert]Tampa, FLBausch Lomb2013
   Google Scholar